New indole-thiazolidine attenuates atherosclerosis in LDLr-/- mice

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 174-180

  César, Fernanda A ^a   Rudnicki, Martina ^a   de las Heras, Beatriz ^b   Boscá, Lisardo ^c   Lima, Maria C A ^d   Pitta, Ivan R ^d   Abdalla, Dulcineia S P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Anti inflammatory; Atherosclerosis; LYSO 7; Thiazolidinediones

Indexed keywords

ANTIINFLAMMATORY AGENT; CD40 ANTIGEN; CD40 LIGAND; CYCLOOXYGENASE 2; GLUCOSE; INDOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; LYSO 7; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-((5-BROMO-1H-INDOL-3-YL)METHYLENE)-3-(4-CHLOROBENZYL)THIAZOLIDINE-2,4-DIONE; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME INHIBITION; EXPERIMENTAL ATHEROSCLEROSIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN RECEPTOR KO MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; TRANSACTIVATION; AGONISTS; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CELL LINE; DEFICIENCY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; INDOLES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, LDL; THIAZOLIDINEDIONES; THIAZOLIDINES;

EID: 84929481346     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.03.009     Document Type: Article

References (32)

1. Fox C.S. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc Med Apr 2010, 20(3):90-95.
2. Puri R., Kataoka Y., Uno K., Nicholls S.J. The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights. Curr Diab Rep Jun 2012, 12(3):280-285.
3. Hamblin M., Chang L., Fan Y., Zhang J., Chen Y.E. PPARs and the cardiovascular system. Antioxid Redox Signal Jun 2009, 11(6):1415-1452.
4. Babaev V.R., Ishiguro H., Ding L., Yancey P.G., Dove D.E., Kovacs W.J., et al. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation Sep 2007, 116(12):1404-1412.
5. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest Dec 2004, 114(11):1564-1576.
6. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest Aug 2000, 106(4):523-531.
7. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol Mar 2001, 21(3):365-371.
8. Ogata M., Tsujita M., Hossain M.A., Akita N., Gonzalez F.J., Staels B., et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis Aug 2009, 205(2):413-419.
9. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell Jan 2001, 7(1):161-171.
10. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature Jan 1 1998, 391(6662):82-86.
11. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature Jan 1 1998, 391(6662):79-82.
12. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation Jan 25 2000, 101(3):235-238.
13. Kung J., Henry R.R. Thiazolidinedione safety. Expert Opin Drug Saf Jul 2012, 11(4):565-579.
14. Patel R.R. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Cardiol Rev May 2009, 17(3):132-135.
15. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev Mar 2002, 18(Suppl. 2):S23-S29.
16. Amato A.A., de Assis Rocha N.F. Idealized PPARgamma-based therapies: lessons from bench and bedside. PPAR Res 2012, 2012:978687.
17. Santin J.R., Uchoa F.D., Lima M.C., Rabello M.M., Machado I.D., Hernandes M.Z., et al. Chemical synthesis, docking studies and biological effects of a pan peroxisome proliferator-activated receptor agonist and cyclooxygenase inhibitor. Eur J Pharm Sci Mar 2013, 48(4-5):689-697.
18. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods May 22 1986, 89(2):271-277.
19. Traves P.G., Hortelano S., Zeini M., Chao T.H., Lam T., Neuteboom S.T., et al. Selective activation of liver X receptors by acanthoic acid-related diterpenes. Mol Pharmacol Jun 2007, 71(6):1545-1553.
20. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem Oct 1982, 126(1):131-138.
21. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, National Research Council. Guide for the care and use of laboratory animals 2011, National Academies Press, Washington. 8 ed.
22. Paigen B., Morrow A., Holmes P.A., Mitchell D., Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis Dec 1987, 68(3):231-240.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods Dec 2001, 25(4):402-408.
24. Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M., et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med May 2013, 19(5):557-566.
25. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem Dec 2002, 277(50):48051-48057.
26. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell Apr 29 2011, 145(3):341-355.
27. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature May 19 2011, 473(7347):317-325.
28. Chira E.C., McMillen T.S., Wang S., Haw A., O'Brien K.D., Wight T.N., et al. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis Nov 2007, 195(1):100-109.
29. Orasanu G., Ziouzenkova O., Devchand P.R., Nehra V., Hamdy O., Horton E.S., et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol Sep 2008, 52(10):869-881.
30. van der Hoorn J.W., Jukema J.W., Havekes L.M., Lundholm E., Camejo G., Rensen P.C., et al. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br J Pharmacol Apr 2009, 156(7):1067-1075.
31. Nakaya H., Summers B.D., Nicholson A.C., Gotto A.M., Hajjar D.P., Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol Jun 2009, 174(6):2007-2014.
32. Lievens D., Eijgelaar W.J., Biessen E.A., Daemen M.J., Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost Aug 2009, 102(2):206-214.